Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study.
Gilmore R, Fernandes R, Hartley I, Arzivian A, Leong R, Andrew B, Vasudevan A, Greeve T, Moore GT, Kim S, Lightowler D, Singh A, Mahy G, Mithanthaya A, Venugopaul K, Han S, Bryant R, West J, Segal J, Christensen B, Corte C, Ding N, An YK, Begun J. Gilmore R, et al. Among authors: christensen b. Intest Res. 2024 Dec 20. doi: 10.5217/ir.2024.00127. Online ahead of print. Intest Res. 2024. PMID: 39709985 Free article.
Insights to aging prediction with AI based epigenetic clocks.
Levy JJ, Diallo AB, Saldias Montivero MK, Gabbita S, Salas LA, Christensen BC. Levy JJ, et al. Among authors: christensen bc. Epigenomics. 2025 Jan;17(1):49-57. doi: 10.1080/17501911.2024.2432854. Epub 2024 Nov 25. Epigenomics. 2025. PMID: 39584810 Review.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy.
Zhang Z, Sehgal K, Shirai K, Butler RA, Wiencke JK, Koestler DC, Ramush G, Lee MK, Molinaro AM, Stolrow HG, Birnbaum A, Salas LA, Haddad RI, Kelsey KT, Christensen BC. Zhang Z, et al. Among authors: christensen bc. NPJ Precis Oncol. 2024 Nov 18;8(1):267. doi: 10.1038/s41698-024-00759-8. NPJ Precis Oncol. 2024. PMID: 39558036 Free PMC article.
1,860 results